drugset
drugset / Trial / NCT03159936

Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)

NCT03159936 ↗

Phase 0 Terminated 5 enrolled Tufts Medical Center Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

Evaluate the activity and safety of oral tofacitinib in adult patients with discoid lupus erythematosus with or without concurrent SLE.

Timeline

Start
2017-04-03
Primary completion
2020-05-13
Completion
2020-06-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tofacitinib Small molecule 10 mg Oral

Indications

discoid lupus erythematosus systemic lupus erythematosus